“Every day we are working to reduce instrument waste, improve surgeon’s performance and minimize total costs with our breakthrough innovations. The big smile on surgeons faces and often their unwillingness to return the instrument after a demonstration are some things that make me passionate about our technology. We are very pleased with the Pharma Trend “Most Innovative Product” Award 2019. It is a true recognition for the practical and technological innovativeness of our steerable, detachable and reusable minimally invasive instruments. Additionally, this award could be a great motivation for new investors in our currently running European equity crowdfunding campaign. Combining innovative excellence, with the right business fundamentals, and external recognition like this award, show that we are ready to disrupt the market of minimally invasive surgery”, stated Dr. Tim Horeman-Franse, CTO and co-founder of Surge-on Medical.

Since the year 2000 the most innovative and sustainable companies in the “Rx” category have been honoured annually, and since 2018 in the categories “OTC”, “Orphan Drugs” and “Startups”, in 2019 the category “Specialty Care” has been added. The decision is based on the Pharma Trend survey, which is conducted among doctors, pharmacists and patients. In the “Startups” category, the winners are determined by a jury of 10 experts with many years of experience in biotechnology, medical technology, M&A and management, as well as in medicine and marketing of pharmaceuticals. The event of Eurecon Media Group is under the patronage of the Bavarian State Ministry of Health and Care. This year, BOCAhealthcare and Surge-on Medical took first and second place in the “Startups” category. Both companies currently run a funding campaign on Aescuvest.

“We congratulate the teams from BOCAhealthcare and Surge-on Medical on this award and are proud that the innovativeness of the two companies presented at Aescuvest.de and Aescuvest.eu has been so prominently acknowledged by independent experts in the form of the Pharma Awards”, says Aescuvest CEO Dr. Patrick Pfeffer. “The experts’ assessment is the same as that of our Investment Committee whose positive opinion is a prerequisite for the launch of a campaign.” Via the platforms that are exclusively geared to healthcare companies, also private investors can participate in start-ups from the most innovative and economically significant sector in Europe. To increase security for investors, an advisory board at Aescuvest reviews the plausibility and innovativeness of each submitted project.

Investors newsletter

Learn how to earn money as a start-up investor and how to avoid the common pitfalls.